Product Description: Tofimilast is an inhibitor of Phosphodiesterase 4 (PDE4) with an IC50 of 0.14 μM. Tofimilast exerts its anti-inflammatory effects by inhibiting the activity of PDE4, thereby increasing intracellular levels of cAMP[1].
Applications: COVID-19-immunoregulation
Formula: C18H21N5S
References: [1]Duplantier AJ, et al. SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase. J Med Chem. 2007 Jan 25;50(2):344-9.
CAS Number: 185954-27-2
Molecular Weight: 339.46
Research Area: Inflammation/Immunology; Neurological Disease
Solubility: 10 mM in DMSO
Target: Phosphodiesterase (PDE)